Oral Cancer News – Page 194 – The Oral Cancer Foundation News Archive

OCF is sad to report the loss of Laura Ziskin to cancer. Ms. Ziskin was an accomplished producer, studio executive and activist / co founder of Stand Up 2 Cancer.

Source: Stand up to Cancer Acclaimed film producer and cancer activist Laura Ziskin died today at her home in Santa Monica at the age of 61. Ziskin, who lived with breast cancer for seven years, is survived by her husband, screenwriter Alvin Sargent, with whom she frequently collaborated; daughter, producer Julia Barry, and son-in-law, writer Eli Dansky. The family requests that donations be made to Stand Up To Cancer: (via http://su2c.org or by mail: Attn: Stand Up To Cancer, c/o The Entertainment Industry Foundation, 1201 West 5th Street., T-700, Los Angeles, CA, 90017.) Ziskin had a trail-blazing career as a producer and studio executive for 35 years. After her cancer diagnosis, Ziskin embraced an additional, unsought role as a cancer activist, joining with other women in the entertainment and media businesses (including Sherry Lansing, Katie Couric, Rusty Robertson, Sue Schwartz, Ellen Ziffren, Pam Williams, Noreen Fraser, and the Entertainment Industry Foundation's Lisa Paulsen and Kathleen Lobb) to co-found Stand Up To Cancer (SU2C). The group marshals the entertainment industry's resources to engage the public in supporting a new approach to cancer research geared toward getting new therapies to patients quickly. Earlier this year, Ziskin was awarded The Producers Guild of America's Visionary Award for her work as a film producer and her humanitarian efforts in the fight against cancer. Speaking of herself and the other SU2C co-founders, Ziskin said, "We realized we had the potential to make cancer the first-tier issue it needs to be and to impact how cancer [...]

Oral Cancer Foundation News Team - A2011-06-14T10:10:00-07:00June, 2011|Oral Cancer News|

Photodynamic therapy shows promise in head/neck cancer

Source: www.drbicuspid.com Author: staff Photodynamic therapy (PDT) has been shown to be effective as a curative therapy for early cancers of the head and neck, according to research presented at the recent International Photodynamic Association World Congress in Innsbruck, Austria. Researchers from Ondine Biomedical presented two studies at the conference. In the first, 469 patients with various neoplastic diseases of the head and neck were treated with PDT with follow-up time of up to 250 months. Patients with primary or recurrent carcinoma in situ and T1 carcinomas responded after one PDT treatment, and 88% remained free of the disease, according to the researchers. The second study focused on the use of PDT to down regulate MMP-9 gene expression in cell cultures of precancerous leukoplakia and oral squamous cell carcinoma. MMP-9 is expressed by squamous cell carcinomas of the head and neck, and is one of the factors responsible for the ability of these cancers to invade into tissue and also to spread to other tissues. After one treatment of methylene blue PDT, gene expression of MMP-9 was significantly decreased in both the precancerous leukoplakia cells and the oral squamous cell carcinoma cells. This work demonstrated that methylene blue mediated PDT can downregulate proteins that promote the spreading of head and neck carcinoma, therefore potentially reducing the ability of these cancers to invade tissue and spread, the researchers noted. "These abstracts clearly confirm a role of PDT in the treatment of head and neck cancer," stated Carolyn Cross, chairman and CEO [...]

Oral Cancer Foundation News Team - A2011-06-14T10:06:50-07:00June, 2011|Oral Cancer News|

Palifermin Decreases Severe Oral Mucositis of Patients Undergoing Postoperative Radiochemotherapy for Head and Neck Cancer: A Randomized, Placebo-Controlled Trial

Source: Journal of Clinical Oncology Purpose: Radiochemotherapy of head and neck cancer causes severe mucositis in most patients. We investigated whether palifermin reduces this debilitating sequela. Methods: We conducted a multicenter, double-blind, randomized, placebo-controlled trial in 186 patients with stages II to IVB carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx. Patients received 60 or 66 Gy after complete (R0) or incomplete resection (R1), respectively, at 2 Gy/fraction and five fractions per week. Cisplatin 100 mg/m2 was administered on days 1 and 22 (and on day 43 with R1). Patients were randomly assigned to receive weekly palifermin 120 μg/kg or placebo from 3 days before and continuing throughout radiochemotherapy. Trained evaluators performed oral assessments twice weekly. The primary end point was the incidence of severe oral mucositis (WHO grades 3 to 4). Overall survival and time to locoregional progression were also assessed. Analysis was by intention to treat. Results: Severe oral mucositis was seen in 47 (51%) of 92 patients administered palifermin and 63 (67%) of 94 administered placebo (P = .027). Palifermin decreased the duration (median, 4.5 v 22.0 days) and prolonged the time to develop (median, 45 v 32 days) severe mucositis. Neither patient-reported mouth and throat soreness scores nor treatment breaks differed between treatment arms. After median follow-up of 32.8 months, 23 deaths (25%) had occurred in both treatment arms, and disease had recurred in 25 (27%) and 22 (24%) of palifermin- and placebo-treated patients, respectively. Conclusion: Palifermin reduced the occurrence of severe oral mucositis in [...]

Oral Cancer Foundation News Team - A2011-06-14T09:57:52-07:00June, 2011|Oral Cancer News|

Certain head and neck cancer patients benefit from second round of treatment

Source: www.eureka.org Author: press release A new study has determined predictors that can better identify patients who will benefit from a potentially toxic second course of treatment, which offers a small but real chance of cure in select patients with head and neck cancer. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the findings could help guide treatment decisions for head and neck cancer patients. Radiation is often used to treat patients with head and neck cancer. If their cancer reappears, they have limited treatment choices: chemotherapy is not curative, and surgery can be curative but is often not possible. Chemotherapy and a second course of radiation have previously been shown to be another option. Joseph Salama, MD, formerly of the University of Chicago, and his colleagues conducted an analysis of prior studies to determine how patients tolerate this second round of treatment and which patients benefit the most from it. The investigators analyzed data from 166 patients with head and neck cancer who received a first round of radiation followed by a second round plus chemotherapy because their cancer recurred or they developed a new tumor. The second course of treatment could cure approximately 25 percent of patients at two years, but it was quite toxic. (Some patients lost the ability to speak or swallow. In addition, approximately 20 percent of patients died from treatment-related complications.) Certain patients benefited from the treatment over others. Those who were cancer-free for a longer period of time, [...]

Oral Cancer Foundation News Team - A2011-06-13T21:30:52-07:00June, 2011|Oral Cancer News|

Is there a relationship between coffee and tea intake and head and neck cancers?

Source: EBD- Evidence Based Dentistry Data sources Pooled individual-level data from nine case–control studies of head and neck cancers, including 5,139 cases and 9,028 controls. Study selection Nine case-control studies were selected from the International Head and Neck Cancer Epidemiology (INHANCE) consortium pool of 33 studies, which included information on coffee (caffeinated and decaffeinated) and tea drinking and cancer of the oral cavity and pharynx. Seven studies also included information on laryngeal cancer. Data extraction and synthesis Data from individual studies were checked for inconsistencies and pooled in a standardised way into a common database, including a range of sociodemographic, behavioural, lifestyle and health information. Data on consumption across studies were then converted into cups of de/caffeinated tea or coffee per day. The association between head and neck cancers and caffeinated coffee, decaffeinated coffee or tea intake was assessed by estimating the odds ratios (OR) and the corresponding 95% confidence intervals (95% CI) using a two-stage random-effects logistic regression model with the maximum likelihood estimator. Pooled ORs were also estimated with a fixed-effects logistic regression model. In addition, a test for heterogeneity among studies was conducted. Results Caffeinated coffee intake was inversely associated with the risk of cancer of the oral cavity and pharynx: the ORs were 0.96 (95% CI, 0.94–0.98) for an increment of one cup per day and 0.61 (95% CI, 0.47–0.80) in drinkers of >4 cups per day versus non-drinkers. This latter estimate was consistent for different anatomic sites (OR, 0.46; 95% CI, 0.30–0.71 for oral cavity; [...]

Oral Cancer Foundation News Team - A2011-06-13T09:58:16-07:00June, 2011|Oral Cancer News|

Targeting Cancer Treatment

Source: Medical News Today Cancer treatment is depending more and more today on specific factors of a patient's tumor, including gene mutations, or proteins that are commonly typical of certain cancer cells, rather than focusing on where in the body the cancer started. Before, treatment was based on finding where in the body the cancer originated, such as the breast or lung. Targeted therapy is all about the cancer's genes, tissue environment that contributes the tumor's growth and survival, and its proteins. Nowadays, cancer therapy is designed to interfere with a signal that tells the cancer cells not to die or tells it to divide, while before, chemotherapies had the goal of interfering with cancer cells as division was already underway, when the cells were dividing into new ones. The human body is made of various types of cells, including skin cells, brain cells, or blood cells. Each one has a specific function. Cancer occurs when healthy cells change and start growing out of control; they eventually form a tumor - a mass. A benign tumor is noncancerous, whereas a malignant one is cancerous, it can spread to other parts of the body. Cancer cells either divide too quickly or do not die when they should do Specific genetic mutations within a cell change the way it behaves. When the genes that control cell division mutate (change), they can multiply too quickly; the cell has become cancerous. Cells are genetically programmed to die, when the specific genes that tell the [...]

Oral Cancer Foundation News Team - A2011-06-13T09:47:33-07:00June, 2011|Oral Cancer News|

Study Confirms Major Side Effects Years After Cancer Treatment

Source: Medical News Today When people finish treatment for cancer, they want to bounce back to their former vital selves as quickly as possible. But a new Northwestern Medicine study - one of the largest survivor studies ever conducted - shows many survivors still suffer moderate to severe problems with pain, fatigue, sleep, memory and concentration three to five years after treatment has ended. "We were surprised to see how prevalent these symptoms still are," said study co-investigator Lynne Wagner, an associate professor of medical social sciences at Northwestern University Feinberg School of Medicine and a clinical health psychologist at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. "This is one of the first looks at what's really happening for survivors in terms of symptoms and treatment among community-based treatment settings across the U.S." The persistent pain in survivors who are cancer-free and no longer receiving any treatment is particularly puzzling, Wagner noted, because good treatment exists. "It seems we haven't come a long way in managing pain despite a lot of medical advances, " she said. "This is eye opening. It tells us we need to be better in clinical practice about managing our survivors' pain." Wagner presented the findings June 4 at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago. Sunday is National Cancer Survivors Day. Cancer survivors seem to slip through the cracks in healthcare in terms of getting treatment for their pain and other symptoms. "We don't have a great system [...]

Oral Cancer Foundation News Team - A2011-06-13T09:33:38-07:00June, 2011|Oral Cancer News|

Head and Neck Cancer Patients Benefit in Multidisciplinary Clinics

Source: Journal of Clinical Oncology Head and neck cancer (HNC) is a multidisciplinary condition. Multi-modality treatment is standard, especially the use of chemoradiation. Proper imaging (CT, MRI and PET), more accurate pathologic assessment and thoroughly tailored treatment plans that limits radiation fields and doses and take into consideration surgical options that minimize morbidity (endoscopic and robotic procedures) are essential. Furthermore, dental, swallowing, speech, nutritional, financial and social support are also cornerstones in this comprehensive approach. However, the most important function might be the role of the nurse navigator in order to offer true coordinated care for our patients. Within William Beaumont Oncology Network we initiated multi-disciplinary clinics for HNC in January 2010 in which our specialists meet the patients together after discussion at the tumor board to streamline management. Methods: In this initial analysis we studied 15 randomly chosen patients’ way through our health care system in 2009, and compared with 15 randomly chosen patients in 2010, after the initiation of the Multi-Disciplinary Clinic. All patients had biopsy verified HNC, the vast majority being squamous cell carcinomas, and were stage III or stage IV. The radiation techniques were unchanged during study and treating physicians remained the same as well. Results: The first group of patients that did not go through our multi-disciplinary clinic had a mean time of 59 days (range 4-156) from pathologic diagnosis to start of radiation. Corresponding mean time for patients going through the multi-disciplinary clinics was 33 days (range 18-86), a decrease of 44%. Conclusions: Coordinated [...]

Oral Cancer Foundation News Team - A2011-06-13T09:22:14-07:00June, 2011|Oral Cancer News|

New Legislation may Weaken FDA’s Regulation of Cigarettes

Source: The Los Angeles Times The U.S. Food and Drug Administration barely had time to start regulating cigarettes before legislation was introduced to weaken its authority. The Family Smoking Prevention and Tobacco Control Act was passed in 2009 with sweeping majorities in both houses; its primary goal was to reduce the terrible toll that smoking takes on Americans' health, especially by discouraging young people from taking up the habit. The law gave the FDA the authority to regulate the advertising and packaging of cigarettes, along with ingredients such as nicotine and flavorings that affect how easily the public is drawn into smoking and how addictive the habit is once started. As required in the law, for example, the FDA banned candy flavorings in cigarettes, which make the product more appealing to underage smokers and young adults. But now that the agency is taking meaningful steps against smoking, Rep. Denny Rehberg (R-Montana) has added an amendment to the agriculture appropriations bill that would restrict the FDA's authority over cigarettes and a host of other matters. Currently, the FDA is considering whether to ban one of the most popular and profitable ingredients — menthol — but Rehberg's amendment would keep it from taking that action. No longer would the FDA be able to consider a substance's tendency to attract smokers or make cigarettes more addictive. Rather, the FDA could only ban or limit ingredients that are found to make the cigarette physically more harmful than existing products. Menthol has not been found [...]

Oral Cancer Foundation News Team - A2011-06-09T09:58:11-07:00June, 2011|Oral Cancer News|

New Strategies used to Identify Changes in Head and Neck Cancers

Source: GenomeWeb Daily News By Andrea Anderson CHICAGO– Researchers are making progress using high-throughput strategies to find previously unappreciated genetic and epigenetic quirks in head and neck cancer — including changes that may prove useful for diagnosing and tracking disease. Johns Hopkins University head and neck cancer research director David Sidransky described some of the work during an education session on molecular biology, targets, and pathways involved in head and neck cancer at the American Society of Clinical Oncology annual meeting here yesterday. Speaking during the same session, JHU oncologist Christine Chung and the University of Chicago's Ezra Cohen touched on strategies for targeting the types of mutations previously reported in head and neck cancer and the rationale behind targeted therapeutics already being tested or considered for the disease, respectively. Past studies have uncovered muted DNA methylation across the genomes of several cancer types, Sidransky explained, though methylation is also bumped up at specific sites in certain tumor types. Consequently, he said, researchers are using strategies such as real-time quantitative methylation-specific PCR (real-time QMSP) to look at methylation shifts in head and neck squamous cell carcinoma. In particular, he described work comparing methylation patterns in saliva and serum samples from individuals with HNSCC to those in samples from more than 800 apparently healthy individuals who are considered 'at-risk' of the disease because of smoking status and other exposures. At least two genes — KIF1A and EDNRB — seem to be more highly methylated in samples from those with HNSCC than [...]

Oral Cancer Foundation News Team - A2011-06-08T09:14:07-07:00June, 2011|Oral Cancer News|